Showing 1021-1030 of 18563 results for "".
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-il-13-inhibitors-in-moderate-to-severe-atopic-dermatitis/37624/Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
https://reachmd.com/programs/cme/chairpersons-perspective-innovative-approaches-to-ibs-c-personalized-treatment-for-better-outcomes/27169/Join us to discover the impact of IBS-C on patients’ QoL and find out how to apply advances in its treatment & management.Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
https://reachmd.com/programs/cme/case-application-frontline-insightstackling-newly-diagnosed-myeloma/36573/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityImpact of Barostim on Heart Failure Hospitalization
https://reachmd.com/programs/cme/impact-of-barostim-on-heart-failure-hospitalization/29818/Considering Barostim™ for heart failure? Tune in to hear our expert review its real-world impact on healthcare utilization and hospital visits.Pruritus In PN and AD: Challenge How You Manage Itch
https://reachmd.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.Diagnosing and Treating IBS: It Begins With One Simple Question
https://reachmd.com/programs/cme/diagnosing-and-treating-ibs-it-begins-with-one-simple-question/36607/Diagnosing and Treating IBS: It Begins With One Simple QuestionFrom Risk to Resilience: Best Practices for Improving Outcomes in Early-Stage ER+/HER2- Breast Cancer
https://reachmd.com/programs/cme/from-risk-to-resilience-best-practices-for-improving-outcomes-in-early-stage-erher2-breast-cancer/32681/Learn about the importance of risk assessment, the role of CDK4/6 inhibitors, and the management of treatment-emergent toxicities in the treatment of HR+, HER2- early breast cancer.Understanding the MOA of NEMLUVIO®: Targeting IL-31 Signaling in Neuroimmune Skin Diseases
https://reachmd.com/programs/nemluvio-peer-network/understanding-the-moa-of-nemluvio-targeting-il-31-signaling-in-neuroimmune-skin-diseases/37128/Watch Dr Peter Lio as he explains the role of IL-31, a key neuroimmune cytokine, in AD and PN and provides an in depth overview of the mechanism of action for NEMLUVIO®.Next-Generation Innovations: The Future of CELMoDs in Myeloma
https://reachmd.com/programs/cme/next-generation-innovations-the-future-of-celmods-in-myeloma/36575/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
https://reachmd.com/programs/cme/patient-centric-adt-intensification-in-hormone-sensitive-prostate-cancer-balancing-efficacy-safety-quality-of-life-and-survival/27147/This education will help clinicians develop evidence-based and collaborative treatment plans for the management of hormone-sensitive prostate cancer (HSPC) with ADT intensification, leading to improved outcomes, reduced ri